Kanglaite Injection (KLTi) / Zhejiang Kanglaite Pharmaceutical - LARVOL DELTA

Retrospective analysis of the curative effect of Kanglaite injection on pancreatic cancer. (PubMed, J Med Biochem) - "In addition, the Chi-square test showed that patients with KLT could reduce the influence on monocyte count and albumin abnormality, which suggested that patients with KLT could reduce adverse reactions. Kanglaite injection combined with conventional radiotherapy and chemotherapy plays a significant role in improving therapeutic effect, immune function, and prolonging survival expression, and it will not increase the incidence of severe adverse reactions."

Journal • Retrospective data • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9 • MUC16

Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis. (PubMed, Front Immunol) - "The results of the network meta-analysis showed that Kanglaite Injection combined with chemotherapy showed a relatively favorable ranking for objective response rate (ORR), CD8, and skin adverse reactions; Kang'ai Injection combined with chemotherapy for hemoglobin reduction-related adverse reactions; Shenqi Fuzheng Injection for natural killer cells (NK cells), immunoglobulin G (IgG), neuron-specific enolase (NSE), and carbohydrate antigen 19-9 (CA19-9); Aidi Injection for immunoglobulin A (IgA), immunoglobulin M (IgM), and bone marrow suppression-related adverse reactions; Fufang Kushen Injection for carcinoembryonic antigen (CEA), vascular endothelial growth factor (VEGF), and adverse reactions such as leukopenia, liver and kidney function damage, and gastrointestinal symptoms; Shenmai Injection combined with chemotherapy for carbohydrate antigen 125 (CA125); Yadanzi Youru injection combined with chemotherapy for squamous cell carcinoma antigen (SCC);..."

Clinical • Journal • Retrospective data • Review • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thrombocytopenia • CA 19-9 • CD4 • CD8 • CEACAM5 • CK19 • KRT19 • MUC16

Evidence mapping analysis of clinical studies on Chinese patent medicines for non-small cell lung cancer from past five years (PubMed, Zhongguo Zhong Yao Za Zhi) - "A total of 25 Chinese patent medicines were involved, among which Aidi Injection, Compound Kushen Injection, and Kanglaite Injection were the most widely used...In summary, the current clinical evidence for Chinese patent medicines in the treatment of NSCLC is characterized by uneven distribution and insufficient methodological quality. There is an urgent need to conduct multicenter collaborative studies, optimize study design and key outcome measures, and strengthen the evaluation of long-term efficacy and health economics to promote the generation of high-quality evidence and its clinical translation."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Safety and Clinical Outcomes of Kanglaite Injection in Combination with Toripalimab and Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Analysis. (PubMed, Cancer Manag Res) - "Dynamic changes in serum VEGF levels were associated with treatment response; however, these findings should be interpreted with caution due to the retrospective design and absence of a control group. Further well-designed prospective controlled studies are warranted to validate these observations."

Clinical data • Journal • Real-world evidence • Retrospective data • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Meta-analysis of the efficacy and safety of Kanglaite Injection in conjunction with chemotherapy for cancer pain. (PubMed, Front Oncol) - "Evidence certainty was moderate for most outcomes per GRADE assessment. The combination of Kanglaite Injection with chemotherapy appears effective and safe in treating cancer pain based on moderate-certainty evidence, pending further high-quality trials."

Journal • Retrospective data • Review • Oncology • Pain

Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis. (PubMed, Front Pharmacol) - "The objective response rate (ORR) was significantly increased by Kanglaite injection (RR = 1.52, 95% confidence interval [CI]: 1.07-2.15, p = 0.02)...Due to limitations in the assessed research, high-quality clinical studies with rigorous designs are required to confirm the findings. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024561845, Identifier CRD42024561845."

Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8

Economics, efficacy and safety of five traditional Chinese medicine injections plus chemotherapy as adjuvant therapy for non-small cell lung cancer: A network meta-analysis. (PubMed, Int J Clin Pharm) - "Among the five TCM injections evaluated, Kangai injection combined with chemotherapy has emerged as the most cost-effective regimen for advanced NSCLC. These findings support the integration of TCM into evidence-based cancer care, and highlight the need for further pharmacoeconomic research, particularly in real-world clinical settings."

Journal • Retrospective data • Review • Hematological Disorders • Hepatology • Leukopenia • Liver Failure • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of Chinese medicine injection combined with concurrent chemoradiotherapy in the treatment of esophageal cancer: a Bayesian network meta-analysis. (PubMed, Front Med (Lausanne)) - "Kanglaite injection (KLT) combined with CCRT (SUCRA: 85.1%; 90.1%) was optimal for enhancing performance status and one-year survival rate...Nevertheless, the findings shall be validated in multicenter, better-designed RCTs. The PRISMA registration details for this study can be found at: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574242."

Journal • Retrospective data • Review • Esophageal Cancer • Oncology • CD4 • CD8

8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy. (PubMed, Front Pharmacol) - "Kanglaite Injection (KLT) combined with chemotherapy had the best effect on reducing tumor markers CEA and CA153. Although a 2021 network meta-analysis (Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis) examined chemotherapy combined with Chinese medicine injections for breast cancer, it was limited to the CF regimen and assessed few outcomes, with some lower-quality studies included (excluded herein)...This provides more comprehensive results, identifying SQFZ as most effective for improving response rate and Karnofsky Performance Status (KPS), thereby enhancing clinical utility. https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier [CRD42024589306]."

Journal • Retrospective data • Review • Breast Cancer • Oncology • Solid Tumor • CD4 • CD8

Beneficial effects of proprietary Chinese medicines as adjuvant therapy in patients with advanced colorectal cancer: A meta-analysis. (PubMed, Medicine (Baltimore)) - "The existing evidence indicates that the combination of 10 traditional Chinese patent medicines and simple preparations, in addition to conventional chemotherapy, can improve the DCR, ORR, and QOL for patients with advanced colorectal cancer. Furthermore, this combination treatment can improve patients' immune function and reduce the adverse reactions associated with chemotherapy. Among them, Yangzheng Xiaoji capsules have the best effect in improving immune function, ORR, DCR, and QOL, Huachansu capsules have the best effect in improving white blood cell count decline and reducing nausea and vomiting after chemotherapy."

Clinical • Journal • Retrospective data • Review • Colorectal Cancer • Oncology • Solid Tumor

Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection. (PubMed, Phytomedicine) - "Our findings verify the therapeutic effects of targeting LIF in SFN-resistance, uncover the potential mechanism for the increased sensitivity to SFN and sought to elucidate how this intervention might contribute to overcoming SFN resistance. KLTI is a promising immunomodulatory drug by regulating LIF and macrophage-NK cell interaction, which could be a potential combination partner for HCC treatment."

Journal • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Oncology • Solid Tumor • LIF

A study on the survival benefit and real-world safety of Kanglaite injection in the treatment of advanced non-small cell lung cancer (CSCO 2024) - "Study group: [Jiangxi Kanglaite Pharmaceutical Co., Ltd.]"

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis. (PubMed, Front Pharmacol) - "Background: Non-small cell lung cancer (NSCLC) poses a serious threat to human health. Astragalus Injection plus DP, Brucea Javanica Oil Milk Injection plus DP, Shenfu Injection plus DP, Kanglaite Injection plus DP, and Brucea Javanica Oil Milk Injection plus DP were significantly effective. However, further multicenter and well-designed RCTs are required to validate our findings."

Combination therapy • Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4

Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview. (PubMed, Curr Treat Options Oncol) - "CAM options such as: medical cannabis, plants, fungi, herbal formulas, and injections, which originate primarily from traditional Chinese or Japanese medicine i.e. Curcuma longa, Panax ginseng, Poria cocos, Hochuekkito, Juzentaihoto, and Rikkunshito, Shi-quan-da-bu-tang/TJ-48, Huang-qin-tang, Shuangbai San, Wen Jing Zhi Tong Fang, Xiang-Sha-Liu-jun-zi-tang, Aidi injection, Brucea javanica oil emulsion/Yadanziyouru injection, Compound Kushen injection, Huachansu injection, Kangai injection and Kanglaite injections are becoming promising candidates for the management of pancreatic cancer. The abovementioned substances/medications are the most popular or potentially effective in PC treatment and consequently CAM-based adjuvant therapy through improving patients' quality of life, might be a useful addition in the treatment of pancreatic cancer patients."

Journal • Review • CNS Disorders • Depression • Gastrointestinal Cancer • Hepatology • Oncology • Pain • Pancreatic Cancer • Psychiatry • Solid Tumor

Critical Response to Article "Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer" [Letter]. (PubMed, Drug Des Devel Ther) - No abstract available

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer. (PubMed, Am J Transl Res) - "Current evidence shows that the combination regimen of KLT with GP has shown promising results in increasing the response rate, improving the KPS score, enhancing the immune level, and reducing the incidence of adverse reactions in NSCLC patients. However, this conclusion needs to be further verified due to limitations such as the limited number of articles included in this paper and the variability in research methodology and quality among the included studies."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4

Network meta-analysis of 8 types of traditional Chinese medicine injection combined with chemotherapy in colorectal cancer treatment. (PubMed, J Cancer Res Clin Oncol) - "Aidi injection, Brucea javanica oil emulsion injection, compound Kushen injection, Kangai injection, Shenqi Fuzheng injection, Kanglaite injection, Shenfu injection, and Xiaoaiping injection combined with chemotherapy functioned more effectively than single chemotherapy did in colorectal cancer treatment. Nevertheless, limited by the treatment quality and methodology of different intervention measures included in the study, this conclusion is expected to be scrutinized in higher-quality and rigorously designed randomized controlled trials. PROSPERO registration No.: CRD42023392398."

Journal • Retrospective data • Review • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Leukopenia • Oncology • Pain • Solid Tumor • Thrombocytopenia

Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer. (PubMed, Drug Des Devel Ther) - "Results from in vitro experiments showed that KLTi inhibited proliferation and migration of TNBC cell lines 231 and 468, induced apoptosis, blocked cells in the G2/M phase, downregulated the mRNA expression of seven G2/M phase-related genes cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 2 (CDK2), and checkpoint kinase 1 (CHEK1), cell division cycle 25A (CDC25A), cell division cycle 25B (CDC25B), maternal embryonic leucine zipper kinase (MELK), and aurora kinase A (AURKA), as well as downregulated CDK1 protein expression and up-regulated protein expression of Phospho-CDK1. By utilizing network pharmacology, molecular docking, and in vitro experiments, KLTi was confirmed to have anti-TNBC effects by arresting cell cycle and inhibiting CDK1 dephosphorylation."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AURKA • CDC25A • CDC25B • CDK1 • CDK2 • CHEK1 • GNRP • MELK

Recent advances in Chinese patent medicines entering the international market. (PubMed, Drug Discov Ther) - "Summarized here are recent advances in the efficacy and molecular mechanisms of these Chinese patent medicines to treat respiratory infectious diseases (Lianhua Qingwen capsules, Jinhua Qinggan granules, and Shufeng Jiedu Capsules), cardiovascular and cerebrovascular diseases (Compound Danshen Dripping Pills, Huatuo Zaizao pills, and Tongxinluo Capsules), cancers (a Kanglaite injection and a Shenqi Fuzheng Injection), and gynecological diseases (Guizhi Fuling Capsules). The hope is that this review will contribute to a better understanding of Chinese patent medicines by people around the world."

Journal • Cardiovascular • CNS Disorders • Gynecology • Infectious Disease • Oncology • Respiratory Diseases • Vascular Neurology • Women's Health

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis. (PubMed, Front Pharmacol) - "The top three in terms of improving performance status were Xiaoaiping, Shenmai, and Kanglaite injections. Nevertheless, additional results from multicenter trials and high-quality studies will bevital to support our findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=326097, CRD42022326097."

Retrospective data • Review • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • CD4 • CD8

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials. (PubMed, Front Pharmacol) - "The 16 CHIs were: Aidi injection (ADI), Huachansu injection (HCSI), oil of Ophiopogon injection (OOMI), disodium cantharidinate and vitamin B6 injection (DCI), Shenfu injection (SFI), Shenmai injection (SMI), Shenqi Fuzheng injection (SQFZI), Chansu injection (CSI), Delisheng injection (DLSI), Fufang Kushen injection (FFKSI), Huangqi injection (HQI), Kangai injection (KAI), Kanglaite injection (KLTI), Shengmai injection (SI), Xiangguduotang injection (XGDTI), and Xiaoaiping injection (XAPI)...SMI + WM and DCI + WM are most likely the optimal CHI to improve disease control rates, survival quality score, and reduce adverse effects. This study has limitations; therefore, higher quality RCTs and real-world evidence are required to support our conclusions."

Journal • Retrospective data • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: An overview of systematic reviews. (PubMed, J Ethnopharmacol) - "Our results suggest that KLTi, whether combined with chemotherapy, radiotherapy, or targeted therapy, has an effect on ORR and quality of life and induces adverse reactions, such as leukopenia, nausea, and vomiting. It may improve patient survival; however, the impact of its low-grade quality on the immune function remains undetermined. Owing to the low reporting quality and methodological quality and high risk of bias of the SRs and the included studies, clinical application of KLTi remains unelucidated; higher-quality SRs and randomized controlled trials are necessary in the future."

Journal • Review • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients. (PubMed, Evid Based Complement Alternat Med) - "The 13 TCMIs included Xiaoaiping injection (XAPI), compound kushen injection (CKSI), Aidi injection (ADI), Brucea javanica oil emulsion injection (BJOEI), Shenmai injection (SMI), Kangai injection (KAI), Astragalus injection (AI), elemene emulsion injection (EEI), Shenfu injection (SFI), Shenqi Fuzheng injection (SIFZI), Kanglaite injection (KLEI), Huachansu injection (HCSI), and lentinan injection (LI). TCMIs can prevent OIPN to some extent, among which SIFZI, SMI, and AI may be the most promising TCMIs. However, given the limitations of current studies, more well-designed, high-quality clinical trials will be needed in the future to validate the benefits of TCMIs."

Journal • Oncology • Solid Tumor

Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Biological Mechanisms of Unsaponifiable Matter in Kanglaite Injection for Pancreatic Ductal Adenocarcinoma. (PubMed, Biomed Res Int) - "USM in KLTi plays an anti-PDAC role by intervening in the cell cycle, inducing apoptosis, and downregulating the NF-κB, MAPK, and PI3K-Akt pathways. It might participate in the pancreatic cancer pathway, and core target groups have diagnostic, survival, and prognosis value biomarker significance."

Biomarker • Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MAPK1 • RELA • TP53

Efficacy of Kanglaite against radiotherapy-induced mucositis in head and neck cancer, a phase II trial. (PubMed, Cancer Radiother) - "A low incidence of grade 3-4 radiation-induced mucositis and no severe acute toxic events, with favorable nutritional status and quality of life, were observed in cancer patients after Kanglaite injection. Our findings highlight the need for a prospective, multicenter, and randomized study to investigate the effect of Kanglaite injection on the reduction of radiation-induced mucositis in patients with head and neck cancer."

Journal • P2 data • Gastrointestinal Disorder • Head and Neck Cancer • Mucositis • Neutropenia • Pain • Solid Tumor